The federal government legalised medical marijuana nationally last week, but with several trials currently underway and a number of biotech companies keen to get in on the ground floor, just how the drug will be administered is part of the research.
It certainly won’t be smoked and there will be none of the usual “high” associated with recreational use of the drug when it is used medicinally.
MGC Pharmaceuticals has revealed today what it hopes the consumer product will actually look like in the form of a nasal drug delivery device.
The Perth-based pharmaceutical company has partnered with Israeli medical company SipNose to test the delivery of cannabinoid compounds through a nasal device to treat severe epilepsy.
The research itself will commence at the Hadassah Medical Centre, Israel’s leading epilepsy research institute.
MGC Pharmaceuticals managing director Nativ Segrev “There is a wealth of evidence available to show that medical cannabis can be an effective solution in the treatment of epilepsy,” he said.
Under the new federal scheme, patients with a valid prescription can possess and use medicinal cannabis products manufactured from cannabis legally cultivated in Australia, provided the supply has been authorised under the Therapeutic Goods Act and relevant state and territory legislation. The changes put medicinal cannabis in the same category as restricted medicinal drugs such as morphine.